Med Ad News had a chat with Bill McEllen, partner at Fingerpaint, who has been named lead of all advertising offices for the agency.

Med Ad News caught up with CDM New York’s new creative leaders for a conversation about what they are hoping to achieve at the agency and the challenges facing healthcare advertising during the COVID-19 pandemic.

Leadership teams from the 2020 Manny Award winners and finalists participated in a Q&A forum to offer their analysis on a variety of healthcare industry themes and trends.

Eli Lilly, Johnson & Johnson and GlaxoSmithKline headline the second annual edition of the Outcomes Creativity Index (OCI), a ranking of pharmaceutical companies and prescription brands according to creativity and innovation. The OCI is an aggregate score-based creative achievement encompassing results from eight leading U.S. and international healthcare awards shows that are tabulated to rank the top 10 pharmaceutical companies and top 10 prescription brands. 

2019 was a good year for the pharma industry, even as questions on value kept coming; but 2020 brought a pandemic that raised an “all hands on deck” attitude as well as business challenges.

While Humira remains the best-selling prescription product worldwide, Keytruda has risen to the No. 2 global rank and is on track to eventually claim the top spot.

2019 was another year of growth for agencies. And when the world turned upside down in 2020 as the COVID-19 pandemic swept across the globe, agencies reached deep into technology and took themselves into the virtual realm.

Scientists, researchers, health officials, regulatory agencies, governments, businesses, universities, and many others across the globe are searching for ways to defeat the coronavirus pandemic.

While the healthcare industry looks for ways to combat COVID-19, the beat goes on for drug manufacturers to continue developing and seeking marketing approval for medicines to treat many diseases and conditions. Here is a look at some of the most notable U.S. new drug approvals from Jan. 1 through April 17, 2020.

As pharma companies bolster their pipelines via multibillion-dollar acquisitions, drug manufacturers continue to heavily invest in the oncology space.